Logotype for Forte Biosciences Inc

Forte Biosciences (FBRX) Q4 2018 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Forte Biosciences Inc

Q4 2018 earnings summary

10 Nov, 2026

Executive summary

  • Lead program Toca 511 & Toca FC remained in a pivotal Phase 3 trial for recurrent high-grade glioma, with 380-patient enrollment completed in September 2018.

  • First interim analysis recommended continuing Toca 5 without modification; the next interim analysis and final analysis were planned for 2019.

Financial highlights

  • FY2018 license revenue was $18.0M, primarily the $16.0M ApolloBio upfront payment and a $2.0M enrollment milestone; FY2017 revenue was $41K.

  • FY2018 R&D expense rose to $51.1M from $29.1M, mainly on higher Phase 3 manufacturing and trial costs; G&A increased to $12.8M from $8.6M.

  • FY2018 operating loss was $45.9M and net loss was $49.0M, versus $37.6M and $38.9M, respectively, in FY2017; basic and diluted loss per share was $2.44.

  • Cash, cash equivalents and marketable securities totaled $96.1M at Dec. 31, 2018, versus $88.7M a year earlier; working capital was $81.2M.

Outlook and guidance

  • Year-end liquidity was expected to fund operations for at least 12 months, though further capital was expected to be needed for ongoing development and commercialization.

  • Toca 5’s second interim analysis was planned for 1H 2019 and final analysis for 4Q 2019, contingent on reaching the specified event thresholds.

  • The NRG Oncology Phase 2/3 trial in newly diagnosed glioblastoma was expected to begin by the end of 2019; planned work included safety and preliminary efficacy evaluation with standard treatments.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Forte Biosciences